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Key questions
What is already known about this subject?
 ► Bioprosthetic valve duration is considered on av-
erage 15 years when implanted in elderly patients; 
however, the lifespan of these valves is shorter 
among younger patients.
 ► Clinical guidelines recommend the use of mechanic 
prosthesis in young patients.
What does this study add?
 ► Reoperation in young patients who have received 
bioprosthetic valve implantation is a frequent event.
 ► In our cohort the relative risk of reoperation among 
patients aged 6070 years was more than three 
times higher with respect to older patients.
How might this impact on clinical practice?
 ► Bioprosthetic valves are implanted to avoid the bur-
den due to long-term anticoagulation, but the fre-
quent occurrence of atrial fibrillation may nullify this 
advantage.
 ► These patients need to be anticoagulated with vita-
min K antagonists.
 ► Self-monitoring and self-management is a safe op-
tion that should be offered to these patients.
AbstrAct
Objective Several factors should be considered when 
a prosthetic heart valve, bioprosthetic valve (BV) or 
mechanical valve is to be implanted: thrombogenicity, life 
expectancy and the risk of reoperation.
Methods We conducted an observational retrospective 
multicentre study among Italian Thrombosis Centers on 
patients with BV on long-term vitamin K antagonist (VKA) 
treatment to evaluate the risk of reoperation and the rate 
of bleeding and thrombotic events.
Results We analysed 612 patients (median age 71.8 
years) with BV on long-term VKA treatment for the 
presence of atrial fibrillation (AF) (78.4%) or other 
indications (21.6%). Thirty-four major bleeding events 
(rate 1.1×100 patient-years) and 29 thromboembolic 
events (rate 0.9×100 patient-years) were recorded, and 
46 patients (rate 1.5×100 patient-years) underwent 
reoperation. The rate of reoperation was higher among 
younger patients: 32.9% in patients <60 years and 3.9% 
in patients ≥60 years (relative risk (RR) 3.8, 95% CI 2.1 to 
7.2; p=0.0001). When patients were analysed according 
to age <65 or ≥65 years and <75 or ≥70 years, younger 
patients still were at higher risk for reoperation (RR 3.1, 
95% CI 1.7 to 6.0 and 3.7, 95% CI 1.7 to 8.6, respectively).
Conclusions Our findings suggest that the threshold of 
65 years for implanting a BV should be carefully evaluated, 
considering the high risk for reoperation and the high 
risk of AF occurrence with persisting need for long-term 
anticoagulation. The high risk for reoperation of young 
patients implanted with BV and the availability of a safer 
and easier way to conduct VKA treatment, such as the use 
of point-of-care devices, should be considered when the 
type of valve must be chosen.
IntROduCtIOn
The selection of the type of valve, biopros-
thetic valve (BV) or mechanical valve (MV), 
in patients who need valve replacement is an 
important decision that seriously influences 
the quality of life of patients, who should 
be actively involved in this choice.1 Several 
factors should be considered for this decision, 
mainly thrombogenicity, life expectancy and 
the risk of reoperation. Because of throm-
bogenicity, mechanical prostheses require 
lifelong anticoagulation and expose the 
patient to both bleeding risk and thrombus 
formation, particularly when anticoagu-
lation is not well managed. On the other 
hand, mechanical prostheses have a longer 
lifespan, reducing the risk of reoperation that 
is the main limitation to BV implantation. BV 
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duration is considered to be on average 15 years when 
implanted in elderly patients; however, the lifespan of 
these valves is shorter among younger patients who show 
accelerated valve deterioration.2 For this reason, clin-
ical guidelines recommend the use of MV prosthesis in 
young patients, indicating the age of less than 60 years 
as the optimal age for the implantation of this kind of 
valve. However, uncertainty still exists for the choice of 
the type of valve for patients in the lifespan between 60 
and 70 years, and recommendations differ from Euro-
pean and American guidelines.1 3 European guidelines 
recommend to use BV after the age of 65 years,1 with 
uncertainty for patients aged 60–65 years. Instead, Amer-
ican guidelines recommend the use of BV after the age 
of 70 years, with an interval of uncertainty for patients 
between 60 and 70 years.3 The use of BV has significantly 
increased over the last years. In the UK the number of 
BV implantations grows from 65.4% to 77.8% between 
2004 and 2009.4 Similarly, the rate of BV implantation 
increased in the Netherlands between 1995 and 20105 
and in the USA between 1999 and 20116 even among 
patients aged 55–64 years, despite the different guideline 
recommendations.1 3
Moreover, with respect to the need for long-life anti-
coagulant treatment, it should be noted that a large 
number of elderly patients develop other indications to 
anticoagulation, mainly atrial fibrillation (AF), so losing 
the advantages of carrying a BV.2 According to the longer 
life expectancy that has been recorded in Western coun-
tries in the recent years, the incidence of AF is progres-
sively growing particularly among patients with heart 
valve diseases, leading to an increasing need for antico-
agulation to prevent thromboembolic stroke. Therefore, 
a growing number of patients who received BV implan-
tation did not stop anticoagulation after the first few 
months after surgery, but are maintained on long-term 
treatment. We have conducted an observational, retro-
spective, multicentre study among Italian Thrombosis 
Centers on patients on long-term anticoagulation for the 
presence of prosthetic heart valves to obtain information 
on the adverse events occurring during follow-up. In this 
study, we report data on patients with BV on long-term 
vitamin k antagonist (VKA) treatment for the presence 
of AF or other indications, with the aim of evaluating the 
risk of undergoing reoperation and the rate of bleeding 
and thrombotic events during anticoagulation.
MetHOds
The FCSA-START Valve Study (PLECTRUM) is an obser-
vational retrospective multicentre study performed in the 
frame of the START Register (Italian Survey on anTtico-
agulated pAtients RegisTer) (NCT02219984)7 conducted 
among 33 centres affiliated to the Italian Federation of 
Anticoagulation Clinics (FCSA). Centres were asked to 
select from their database patients in whom a mechan-
ical or biological heart valve prosthesis was implanted 
after 1990 and who were followed for the management 
of anticoagulation treatment. Six hundred and twelve 
patients who received BV implantation and who have 
indication to maintain anticoagulation after the standard 
course of 3 months were enrolled. Patients followed by 
FCSA centres for anticoagulant management receive 
adequate education on the purpose of the treatment, 
the risk of complications, international normalised ratio 
(INR) values and drug dosage management. The centres 
perform periodic INR measurements, prescribe the daily 
VKA dosages and schedule the date for the subsequent 
visits; they monitor and record changes in patients’ habits, 
diet, comedications, intercurrent illnesses, bleeding and 
thrombotic complications during follow-up through 
patient interviews. All centres take part in the specifically 
designed laboratory external quality control programme, 
which runs three times yearly and uses lyophilised plasma 
samples obtained from anticoagulated patients.8
Patients
Patients’ demographic information and clinical data 
were collected. Patients were classified as hypertensive 
if they were taking medications to lower blood pressure. 
Diabetes mellitus was defined according to American 
Diabetes Association criteria.9 Coronary artery disease 
was defined on the basis of a history of myocardial infarc-
tion or stable and unstable angina. Heart failure was 
defined as the presence of signs and symptoms of right or 
left ventricular failure or both and confirmed by non-in-
vasive or invasive measurements demonstrating objective 
evidence of cardiac dysfunction.
Follow-up and endpoints
In the routine practice of the participating centres 
follow-up visits were scheduled every 2–4 weeks for INR 
monitoring. Patients who missed check-ups for >2 months 
were contacted (personally or through their family or 
general practitioner), and the reason for interrupting 
treatment monitoring was recorded. In the case of death, 
further information about its cause was requested. Deaths 
for all causes were recorded. The major endpoint of the 
study was the occurrence of reoperation. The character-
istics of these patients, the cause of reoperation and the 
time intercourse from the first prosthetic valve implant 
were recorded. Secondary endpoints were thrombotic 
event (stroke, transient ischaemic attack (TIA), periph-
eral emboli, valve thrombosis) and major bleeding. 
Stroke was defined as a syndrome characterised by rapidly 
developing clinical symptoms and/or signs of focal and at 
times global loss of brain function, lasting >24 hours, and 
with no apparent cause other than vascular. Ischaemic 
stroke was defined as a stroke with either a normal brain 
CT or evidence of a recent infarction in the clinically 
relevant area of the brain on a CT or MR scan within 3 
weeks of the event, while TIA was diagnosed when neuro-
logical defects lasted <24 hours. Peripheral embolism was 
diagnosed when proved with angiography or thrombec-
tomy. Major bleeding was defined accordingly with the 
definition reported by Palareti et al,10 taking into account 
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Table 1 Characteristics of patients with biological heart 
prosthesis and adverse events during anticoagulant 
treatment
n 612
Male (%) 324 (52.9)
Median age (range) 71.8 (24–89)
Total follow-up (patient-years) 3085
Median follow-up (range) 2.4 (0.5–7.5)
Indications for long-term anticoagulation, n (%) 
  Atrial fibrillation 480 (78.4)
  History of stroke/TIA 13 (2.1)
  Cardiac diseases 22 (3.6)
  Other indications for VKA 6 (1.0)
  Unknown 91 (14.8)
Clinical characteristics, n (%) 
  Hypertension 438 (71.6)
  Diabetes mellitus 121 (19.8)
  Coronary artery disease-peripheral 
arteriopathy
246 (40.2)
  Heart failure 124 (20.3)
  Previous stroke/TIA 77 (12.6)
  Antiplatelet treatment 195 (31.9)
Adverse events, n (rate) 
  Major bleeding 34 (1.1)
  Stroke/TIA 29 (0.9)
  Death 36 (1.2)
TIA, transient ischaemic attack; VKA, vitamin k antagonist.
the definition in use in Italian centres in the study period. 
Follow-up was stopped after the first adverse event 
occurred or when a patient was no longer monitored by 
the participating centre.
statistical analysis
Baseline characteristics were summarised with descriptive 
statistics. Categorical variables were reported as counts 
and percentages and continuous variables were expressed 
as median and IQR. Incidence rates of adverse events 
were calculated as the number of events per 100 patient-
years of observation, and rate ratios were given with their 
95% CIs. For this calculation, observation started at the 
beginning of follow-up and ended when patients experi-
enced a major outcome or were censored. Analyses were 
performed with the Fisher’s exact test (categorical data), 
unpaired t-test (normally distributed data) and Mann-
Whitney test (non-normally distributed data). All vari-
ables found to be significant at univariate analysis were 
subsequently entered in a multivariate analysis. Risk was 
expressed as OR with its 95% CI. A two-sided value of 
p<0.05 was chosen for statistical significance.
The SPSS software for Windows V.20 (SPSS) and Stata 
V.14 statistical software package (StataCorp, College 
Station, TX) were used for data processing.
Results
We analysed 612 patients (52.9% men, median age 71.8 
years) with BV who were on long-term VKA treatment 
for the presence of AF (78.4%) or other indications to 
anticoagulation (21.6%). Patients were followed up for a 
median time of 2.4 years. The characteristics of patients 
are listed in table 1. During follow-up 38 patients died: 6 
for major bleeding, 1 acute myocardial infarction, 1 for 
sudden death, 6 for sepsis, 5 for cancer, 6 for unknown 
reasons and 13 for heart failure. Among the patients 
who died of heart failure, two underwent reoperation 
for structural valve deterioration and died a few months 
later, two were implanted at 51 and 59 years, and nine 
after 70 years of age. For these 11 patients no informa-
tion on valve deterioration is available. Thirty-four major 
bleeding events (rate 1.1×100 patient-years) and 29 
thromboembolic events (rate 0.9×100 patient-years) were 
recorded. Forty-six patients (7.5%, rate 1.5×100 patient-
years) undergo reoperation: 11 (24%) for endocarditis 
and 35 (76%) for structural valve deterioration (table 2). 
Reoperation occurred a median time of 84 months after 
prosthesis implantation. This interval was shorter (median 
time 14 months) for patients who needed reoperation for 
infections with respect to patients with structural valve 
deterioration (median time 9.2 years). The percentage of 
reoperation was higher among younger patients: 32.9% 
among patients <60 years and 3.9% among patients ≥60 
years (relative risk RR 3.8, 95% CI 2.1 to 7.2, p=0.0001). 
When patients were analysed according to age <65 or ≥65 
years and <70 or ≥70 years, younger patients still were at 
higher risk for reoperation (RR 3.1, 95% CI 1.7 to 6.0, 
p=0.0001 and 3.7, 95% CI 1.7 to 8.6, p=0.0001, respec-
tively). Patients who needed reoperation were similar to 
patients who did not for associated comorbidities, except 
for age and the presence of AF (table 3).
dIsCussIOn
Choosing the optimal heart valve prosthesis is a chal-
lenging decision, in particular to middle-aged patients, 
due to the limited duration of BVs and to the increased 
life expectancy of the population, with a prolonged active 
life. The principal finding of this multicentre retrospec-
tive observational study is the confirmation that reopera-
tion among young patients who have received BV implan-
tation is a frequent event. In our cohort, the RR of reop-
eration among patients aged 60–70 years was more than 
three times higher with respect to older patients. The 
need for reoperation after BV implantation is the conse-
quence of infective endocarditis or of structural valve 
deterioration. Endocarditis affects similarly patients with 
BV and patients with MV, with a reported risk ranging 
from 0.24 to 0.54×100 patient-years.11 Instead, structural 
valve deterioration is a rare complication among patients 
with MV and a frequent event among patients with BV. 
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Table 2 Characteristics of patients undergoing valve 
prosthesis reimplantation
n (%) 46 (7.5)
Median age (range) 59.9 (24–79)
Male, n (%) 24 (52.2)
Median time interval to reimplant (months) 84 (1–312)
Site of first implantation, n (%)
  Aortic 30 (65.2)
  Mitral 14 (30.4)
  Mitroaortic 2 (4.3)
Median time interval to reoperation (months) 84 (1–312)
Cause of reoperation, n (%)
  Infection 11 (23.9)
  Prosthetic valve deterioration 35 (76.1)
Median time interval to reimplant, months (range)
  Due to infection 14 (2–72)
  Due to valve deterioration 114 (1–312)
Median age of patients, years (range)
  With infections 69.8 (31–78)
  With structural valve deterioration 55.8 (24–79)












Median age (range) 72.6 (27–89) 56.7 (24–79) 0.0001
Valve position, n (%) 
  Aortic 335 (59.1) 29 (64.4)
  Mitralic 157 (27.7) 14 (31.1)
  Both 75 (13.2) 2 (4.5) 0.2
Comorbidity, n (%) 
  Hypertension 402 (70.9) 36 (80.0) 0.4
  Diabetes mellitus 110 (19.4) 11 (24.4) 0.6
  Coronary artery 
disease
131 (23.1) 13 (28.9) 0.5
  Atrial fibrillation 450 (79.4) 30 (66.7) 0.05
  Previous stroke/TIA 69 (12.2) 8 (17.8) 0.3
  Heart failure 113 (19.9) 11 (24.4) 0.7
  eGFR <30 mL/min 12/273 (4.4) 1/26 (3.8) 1.0
  Smoking habitus 118 (20.8) 12 (26.7) 0.4
  Antiplatelet treatment 185 (32.6) 10 (22.2) 0.2
eGFR, estimated glomerular filtration rate; TIA, transient ischaemic 
attack.
BVs have an expected life of average 15 years.2 A rate 
of reoperation due to structural valve deterioration has 
been reported in 1.9% of patients after 10 years and in 
15% at 20 years.12 Accordingly, a study from Chiang et al13 
reported a rate of reoperation of 12.1% after 15 years. 
More recently, Goldstone et al14 reported a percentage 
of reoperation of 14.8% among patients aged <70 years, 
similarly to the percentage recorded in our study. Reop-
eration carries a high mortality rate,13 15 16 even if the use 
of minimal access approaches may reduce this risk. Simi-
larly, the recent availability of the technique of valve-in-
valve procedure in patients with structural valve deteri-
oration is an option to be considered to lower the risk 
of reoperation.17 18 However, there is limited experience 
with this procedures and long-term follow-up is limited.19
When an MV is implanted the need for reoperation is 
rare14 20; however, long-term anticoagulation is required 
to avoid thrombus formation. The bleeding risk associ-
ated with anticoagulation is a limitation to use of MVs, 
influencing patients and physicians’ choice. Bleeding 
risk is reduced when anticoagulation intensity is lower21 
and when adequate INR monitoring is achieved.22 23 With 
the introduction of direct oral anticoagulants (DOAC), 
which showed to be non-inferior to VKAs for stroke 
prevention with a significant lower bleeding risk in 
patients with AF, it was expected a similar improvement 
even in patients with prosthetic heart valves. However, the 
results of RE-ALIGN trial24 demonstrated an increase of 
both bleeding and thrombotic risks among patients with 
MV, leading to the premature stopping of the trial. At the 
moment, no large randomised trials on the use of DOACs 
in patients with MV are ongoing and these patients need 
to be anticoagulated with VKAs. Therefore, with increased 
frequency BVs are implanted to avoid the burden due to 
long-term anticoagulation. The frequent occurrence of 
AF may nullify this advantage. AF is a frequent cardiac 
arrhythmia at high embolic risk and there is strong 
evidence of the advantage of anticoagulation for stroke 
prevention.25 Its incidence is growing with age and there 
are no studies that evaluate the outcomes of patients with 
BV already on anticoagulation because of AF,2 even if it 
should be noted that these patients, although different 
from MV patients, can be treated also with DOACs.25 
VKAs have been demonstrated to be highly effective in 
the prevention of thromboembolism among patients 
with MVs and are still used by millions of patients world-
wide.26 It has been well defined that a strong association 
exists between the quality of anticoagulation control, 
evaluated as time in therapeutic range (TTR),27 and the 
occurrence of adverse events.28 Among patients with MV 
on long-term VKA treatment the direct involvement of 
the patient itself in the management of the anticoagu-
lation has been successfully reported. The availability of 
accurate point-of-care devices allows the self-testing by 
the patients, who can have the INR results managed by 
the responsible physician (self-testing) or can be trained 
to adjust the drug dosage according to the INR results 
(self-management). This modality has been widely used 
in Germany due to the availability of reimbursement for 
these devices in this country. A higher TTR was obtained 
among patients on self-management compared with 
patients on routine care monitoring.29 Moreover, it has 
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been reported that self-monitoring was superior to usual 
care with 49% (HR 0.51, 95% CI 0.31 to 0.85) risk reduc-
tion of thromboembolic events.30 The advantage over the 
routine care was higher mainly among younger patients 
and particularly in those with MVs.30 Patients with MV are 
younger than patients on VKAs for other indications, and 
are highly aware of thromboembolic risks, with particular 
willingness to simplify their treatment and have a better 
quality of life. It should be noted that bleeding rates are 
not reduced among patients on self-monitoring, and no 
major effect on mortality has been reported.22 Several 
studies show that self-monitoring and self-management 
is a safe option for suitable patients and this is an option 
that should be offered to all patients who need long-term 
VKA treatment.22
lIMItatIOns
We are aware of the limitations of our study. First, this 
is an observational retrospective cohort study, and there-
fore we could not adjust for clinical information that was 
not recorded. Second, our observation excluded patients 
without indication to long-term anticoagulation. There-
fore, we cannot evaluate the outcome of these patients. 
Third, for 11 patients no information on valve deteriora-
tion was available.
The strengths of our study are the multicentre design, 
and the prospective recording of the adverse events and 
of anticoagulation history routinely done by participating 
centres in electronic databases.
In conclusion, our findings suggest that the threshold 
of 65 years for implanting a BV should be carefully eval-
uated, considering the high risk for reoperation and the 
high risk of AF occurrence with persisting need for long-
term anticoagulation. The high risk for reoperation of 
young patients implanted with BV and the availability of 
a safe and easy way to conduct VKA treatment should be 
considered when the type of valve must be chosen.
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